Mark Crowther

Mark Crowther

Auto-generated profile, based on publicly available information

Mark Crowther

Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Chest
Verified
Journal Article
Closed access
JAJack Ansell
Jack Ansell
JHJack Hirsh
Jack Hirsh
EHElaine Hylek
Elaine Hylek
AJAlan Jacobson
Alan Jacobson
MCMark Crowther
Mark Crowther
GPGualtiero Palareti
Gualtiero Palareti

21 April 2011 in Blood
Verified
Journal Article
Open access
PDF file
CNCindy Neunert
Cindy Neunert
WLWendy Lim
Wendy Lim
MCMark Crowther
Mark Crowther
ACAlan Cohen
Alan Cohen
LSLawrence Solberg
Lawrence Solberg
MCMark A. Crowther
Mark A. Crowther
Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the American Society of Hematology published a landmark guidance paper designed to assist clinicians in the management of this disorder. Since 1996 there have been numerous advances in the management of both adult and pediatric ITP. These changes mandated an update in the guidelines. This guideline uses a rigorous, evidence-based approach to the location, interpretation, and presentation of the available evidence. We have endeavored to identify, abstract, and present all available methodologically rigorous data informing the treatment of ITP. We provide evidence-based treatment recommendations using the GRADE system in those areas in which such evidence exists. We do not provide evidence in those areas in which evidence is lacking, or is of lower quality—interested readers are referred to a number of recent, consensus-based recommendations for expert opinion in these clinical areas. Our review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of “front-line” therapy for ITP, the management of serious bleeding in patients with ITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention.

1 February 2012 in Chest
Verified
Journal Article
Closed access
WAWalter Ageno
Walter Ageno
AGAlexander S. Gallus
Alexander S. Gallus
AWAnn Wittkowsky
Ann Wittkowsky
MCMark Crowther
Mark Crowther
EHElaine M. Hylek
Elaine M. Hylek
GPGualtiero Palareti
Gualtiero Palareti

1 February 2012 in Chest
Verified
Journal Article
Closed access
AHAnne M Holbrook
Anne M Holbrook
SSSam Schulman
Sam Schulman
DWDaniel M. Witt
Daniel M. Witt
PVPer Olav Vandvik
Per Olav Vandvik
JFJason Fish
Jason Fish
GGGordon H. Guyatt
Gordon H. Guyatt

1 March 2014 in Anesthesiology
Verified
Journal Article
Closed access
FBFernando Botto
Fernando Botto
PAPablo Alonso
Pablo Alonso
MCMatthew TV Chan
Matthew TV Chan
JVJuan Villar
Juan Villar
DXDenis Xavier
Denis Xavier
TWTroy Wildes
Troy Wildes
Background: Myocardial injury after noncardiac surgery (MINS) was defined as prognostically relevant myocardial injury due to ischemia that occurs during or within 30 days after noncardiac surgery. The study’s four objectives were to determine the diagnostic criteria, characteristics, predictors, and 30-day outcomes of MINS. Methods: In this international, prospective cohort study of 15,065 patients aged 45 yr or older who underwent in-patient noncardiac surgery, troponin T was measured during the first 3 postoperative days. Patients with a troponin T level of 0.04 ng/ml or greater (elevated “abnormal” laboratory threshold) were assessed for ischemic features (i.e., ischemic symptoms and electrocardiography findings). Patients adjudicated as having a nonischemic troponin elevation (e.g., sepsis) were excluded. To establish diagnostic criteria for MINS, the authors used Cox regression analyses in which the dependent variable was 30-day mortality (260 deaths) and independent variables included preoperative variables, perioperative complications, and potential MINS diagnostic criteria. Results: An elevated troponin after noncardiac surgery, irrespective of the presence of an ischemic feature, independently predicted 30-day mortality. Therefore, the authors’ diagnostic criterion for MINS was a peak troponin T level of 0.03 ng/ml or greater judged due to myocardial ischemia. MINS was an independent predictor of 30-day mortality (adjusted hazard ratio, 3.87; 95% CI, 2.96–5.08) and had the highest population-attributable risk (34.0%, 95% CI, 26.6–41.5) of the perioperative complications. Twelve hundred patients (8.0%) suffered MINS, and 58.2% of these patients would not have fulfilled the universal definition of myocardial infarction. Only 15.8% of patients with MINS experienced an ischemic symptom. Conclusion: Among adults undergoing noncardiac surgery, MINS is common and associated with substantial mortality.

18 September 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MCMark A. Crowther
Mark A. Crowther
JGJeff S. Ginsberg
Jeff S. Ginsberg
JJJim Julian
Jim Julian
JDJudah Denburg
Judah Denburg
JHJack Hirsh
Jack Hirsh
MKMichael J. Kovacs
Michael J. Kovacs
Many patients with the antiphospholipid antibody syndrome and recurrent thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) of more than 3.0. However, there are no prospective data to support this approach to thromboprophylaxis. We performed a randomized, double-blind trial in which patients with antiphospholipid antibodies and previous thrombosis were assigned to receive enough warfarin to achieve an INR of 2.0 to 3.0 (moderate intensity) or 3.1 to 4.0 (high intensity). Our objective was to show that high-intensity warfarin was more effective in preventing thrombosis than moderate-intensity warfarin. A total of 114 patients were enrolled in the study and followed for a mean of 2.7 years. Recurrent thrombosis occurred in 6 of 56 patients (10.7 percent) assigned to receive high-intensity warfarin and in 2 of 58 patients (3.4 percent) assigned to receive moderate-intensity warfarin (hazard ratio for the high-intensity group, 3.1; 95 percent confidence interval, 0.6 to 15.0). Major bleeding occurred in three patients assigned to receive high-intensity warfarin and four patients assigned to receive moderate-intensity warfarin (hazard ratio, 1.0; 95 percent confidence interval, 0.2 to 4.8). High-intensity warfarin was not superior to moderate-intensity warfarin for thromboprophylaxis in patients with antiphospholipid antibodies and previous thrombosis. The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome.